Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co Ltd is a Chinese pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the domestic market.
Business. Fujian Cosunter Pharmaceutical Co Ltd (300436.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Fujian Cosunter Pharmaceutical Co Ltd (300436.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Fujian Cosunter Pharmaceutical Co Ltd exhibits a weak capital structure and liquidity position, with a debt-to-equity ratio of 1.64 and a current ratio of 1.08, indicating limited short-term liquidity. The company's free cash flow is negative at -223.6 million CNY, and operating cash flow is also negative at -35.1 million CNY, suggesting ongoing cash flow challenges. The negative net cash position after subtracting total debt further highlights the company's liquidity risk.
Profitability metrics are severely underperforming relative to industry norms, with a return on equity of -78.5% and a return on assets of -15.56%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of 228.4 million CNY and a net loss of 217.8 million CNY for the period further underscore the company's financial distress.
The company's revenue is concentrated in a single geographic market, with no disclosed international operations, making it highly sensitive to domestic economic and regulatory shifts. No segment-specific revenue breakdown is available, but the lack of diversification increases exposure to localized risks.
Growth prospects appear dim, with the company reporting a net loss and negative cash flows. No specific revenue growth rate is provided, but the financial performance suggests a contraction in operations rather than expansion. The capital expenditure of -59.5 million CNY indicates a reduction in investment, which may signal a defensive financial strategy.
The company faces significant financial risk, with a medium liquidity risk rating and a negative operating cash flow. The debt-to-equity ratio of 1.64 suggests a high reliance on debt financing, which could become a burden if interest rates rise or if the company is unable to service its obligations. The risk of dilution is currently low, but the company's financial position may necessitate equity issuance in the future.
No recent events or filings are disclosed in the available data, but the company's financial performance and liquidity position suggest a need for close monitoring of future disclosures and strategic actions.
- Fujian Cosunter Pharmaceutical Co Ltd is experiencing significant financial distress, with negative net income and operating cash flow.
- The company's debt-to-equity ratio of 1.64 and current ratio of 1.08 indicate weak liquidity and capital structure.
- Return on equity and return on assets are both negative, highlighting poor profitability and asset utilization.
- The company's operations are concentrated in a single geographic market, increasing exposure to localized risks.
- Growth prospects are limited, with no evidence of expansion or investment in capital expenditures.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Fujian Cosunter Pharmaceutical Co Ltd Market data — financials · 2026-05-26